AstraZeneca (LSE:AZN) has agreed a new five year national partnership with YMCA of the USA to expand community based cancer education, screening, and survivorship support. The company also received US ...

AZN's Ultomiris wins FDA priority review for IgAN, backed by late-stage data showing a 43.4% proteinuria reduction versus ...

FDA grants Priority Review to AstraZeneca’s Imfinzi sBLA for muscle-invasive bladder cancer, with decision expected in Q2 2025. Imfinzi regimen showed a 32% reduced risk of disease progression and a ...

WILMINGTON, DE — The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) in ...

AstraZeneca ( (GB:AZN)) has issued an update. AstraZeneca has secured U.S. approval for its AKT inhibitor Truqap (capivasertib) in combination with abiraterone and prednisone as the first targeted ...

(Reuters) -AstraZeneca said on Thursday the U.S. Food and Drug Administration (FDA) has granted its blockbuster cancer drug Imfinzi a priority review for patients with limited-stage small cell lung ...

On Thursday, the FDA accepted and granted Priority Review to AstraZeneca Plc’s (NASDAQ:AZN) supplemental marketing application for Calquence (acalabrutinib) for adult patients with previously ...

(RTTNews) - AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application for Enhertu in combination with pertuzumab has been accepted and granted Priority Review in the US for the first ...

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AstraZeneca (LSE:AZN) has agreed a new five year national partnership with YMCA of the USA ...